Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 81 results
Author Title [ Type(Asc)] Year
Filters: Author is Moore, John P  [Clear All Filters]
Journal Article
Sanders RW, Moore JP.  2024.  Progress on priming HIV-1 immunity.. Science. 384(6697):738-739.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..  2021.  Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, Wu W, van der Straten K, Agrawal S, Derking R, Reiss EIMM, Millard K et al..  2025.  Precise targeting of HIV broadly neutralizing antibody precursors in humans.. Science. 389(6759):eadv5572.
Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, Wang S-K, Stanfield RL, Julien J-P, Ramos A, Crispin M et al..  2011.  A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.. Science. 334(6059):1097-103.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..  2021.  Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Moore JP, Kuritzkes DR.  2009.  A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.. Curr Opin HIV AIDS. 4(2):118-24.
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Resto YAlemán, Alsibaee A, Alzualde A et al..  2016.  Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.. PLoS Pathog. 12(7):e1005763.
Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP.  2008.  N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.. Virology. 372(1):187-200.
Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJohan, Mitchnick M, Goldman L, Doyle LA, Muldoon BCO et al..  2011.  Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.. J Control Release. 156(2):161-9.
Pugach P, Ketas TJ, Michael E, Moore JP.  2008.  Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.. Virology. 377(2):401-7.
Sanders RW, Moore JP.  2017.  Native-like Env trimers as a platform for HIV-1 vaccine design.. Immunol Rev. 275(1):161-182.
Berro R, Klasse PJohan, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP.  2011.  Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.. J Virol. 85(16):8227-40.
Behrens A-J, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M.  2017.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.. J Virol. 91(2)
Prabhu M, Yang YJ, Johnston CD, Murphy EA, Ketas TJ, Díaz-Tapia R, Jurkiewicz M, Racine-Brzostek S, Mohammed I, Sukhu AC et al..  2023.  Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.. Am J Obstet Gynecol MFM. 5(2):100796.
Burton DR, Hessell AJ, Keele BF, Klasse PJohan, Ketas TA, Moldt B, D Dunlop C, Poignard P, Doyle LA, Cavacini L et al..  2011.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.. Proc Natl Acad Sci U S A. 108(27):11181-6.
Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K et al..  2010.  Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.. Virology. 401(2):236-47.
Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW et al..  2015.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.. J Virol. 89(23):12189-210.
Pugach P, Ray N, Klasse PJohan, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP.  2009.  Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.. Virology. 387(2):296-302.
Klasse PJ, Nixon DF, Moore JP.  2021.  Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.. Sci Adv. 7(12)
Brouwer PJM, Antanasijevic A, de Gast M, Allen JD, Bijl TPL, Yasmeen A, Ravichandran R, Burger JA, Ozorowski G, Torres JL et al..  2021.  Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles.. NPJ Vaccines. 6(1):24.
Nelson AN, Shen X, Vekatayogi S, Zhang S, Ozorowski G, Dennis M, Sewall LM, Milligan E, Davis D, Cross KA et al..  2024.  Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques.. Sci Immunol. 9(98):eadm7097.
Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP.  2010.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.. AIDS Res Hum Retroviruses. 26(4):445-58.
Klasse PJohan, Sanders RW, Cerutti A, Moore JP.  2012.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses. 28(1):1-15.
Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, Dodd J, Dean H, Sattentau Q, Montefiori D et al..  2023.  HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.. PLoS One. 18(10):e0293148.